MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Vaccines & Vaccination Open Access
ISSN: 2578-5044

Dengue Infection, its Diagnosis, Treatment, and Vaccination: A Narrative Review

Inayat F[1]*, Ullah MJ[2] and Tariq I[3]

[1]Department of Biochemistry, Abdul Wali Khan University, Pakistan
[2]Department of Allied Health Sciences, Iqra National University, Pakistan
[3]Department of Health and Biological Sciences, Abasyn University Peshawar, Pakistan

***Corresponding author:** Fawad Inayat, Department of Biochemistry, Abdul Wali Khan University, Pakistan, Email: fawad.313b@gmail.com

Review Article
Volume 8 Issue 1
Received Date: April 04, 2023
Published Date: April 10, 2023
DOI: 10.23880/vvoa-16000156

Abstract

Dengue infection is a significant public health issue globally, particularly in tropical and subtropical regions, and is caused by a virus transmitted by Aedes mosquitoes. It can range from mild fever to severe forms, such as hemorrhagic fever and shock syndrome, with high mortality rates. Management involves supportive care to alleviate symptoms and prevent complications, while early detection and prompt management of symptoms can significantly reduce the risk of severe forms of the disease. A dengue vaccine has been developed, with several vaccine candidates undergoing clinical trials to evaluate their efficacy and safety. The vaccine has shown promising results in preventing dengue infection and reducing the severity of the disease. Preventing dengue infection requires a multifaceted approach, including reducing mosquito breeding sites, controlling mosquito populations, and educating the public on prevention measures. Vector control measures, such as the use of insecticides and larvicides, have been effective in reducing mosquito populations, but their sustainability remains a challenge. The development of an effective and safe dengue vaccine is urgently needed, with ongoing research efforts aiming to develop a vaccine that is safe and effective for all age groups and provides broad protection against all serotypes. Limitations of the study include the potential lack of consideration of regional variations in dengue epidemiology and control measures, and the absence of a detailed analysis of the economic and social impacts of dengue infection on affected populations. In conclusion, continued investment in research and development of effective prevention and treatment strategies is crucial to combat this disease and reduce its impact on affected populations.

Keywords: Dengue Infection; Dengue Infection Treatment; Dengue Vaccination

Abbreviations: DHF: Dengue Hemorrhagic Fever; DSS: Dengue Shock Syndrome; ELISA: Enzyme-Linked Immune Sorbent Assay; RDT: Rapid Diagnostic Test; PCR: Polymerase Chain Reaction; CT: Computed Tomography; WHO: World Health Organization; APCs: Antigen-Presenting Cells.

Introduction

Dengue is a viral disease transmitted to humans by the Aedes mosquito. It is prevalent in tropical and subtropical regions of the world, including Southeast Asia, Central and South America, Africa, and the Caribbean [1]. The virus

causing dengue has four different serotypes, which means that a person can be infected with dengue multiple times. Each infection with a different serotype may lead to more severe symptoms. The symptoms of dengue typically include a sudden onset of high fever, severe headache, joint and muscle pain, rash, and eye pain. In severe cases, dengue can cause bleeding, shock, and even death [2]. There is no specific treatment for dengue, and management typically involves supportive care to relieve symptoms and prevent complications. Prevention efforts include controlling the mosquito population through measures such as using insecticides, eliminating standing water where mosquitoes breed, and using protective clothing and mosquito repellent [3].

History of Dengue Infection

Dengue fever is an ancient disease, and historical records of outbreaks and epidemics date back to the 18th century [4]. The disease was first described during an outbreak in the Philippines in 1953, and its name comes from the Swahili phrase "ki denga pepo," which means "cramp-like seizure caused by an evil spirit [5]." In the early 20th century, dengue was a major health problem in Southeast Asia. In the 1950s and 1960s, the disease spread to other parts of the world, including Africa, the Americas, and the Pacific. The first major epidemic of dengue hemorrhagic fever (DHF), a severe form of the disease that can be fatal, occurred in the Philippines in 1953-1954 [6]. Since then, DHF has become a significant public health concern in many countries with dengue transmission. During the 1970s and 1980s, the incidence of dengue increased dramatically in many parts of the world, including Southeast Asia, the Western Pacific, and the Americas [7]. This increase was likely due to several factors, including rapid urbanization, increased international travel and trade, and inadequate mosquito control measures. In recent decades, the incidence of dengue has continued to rise, and the disease is now a leading cause of illness and death in many countries, particularly in the tropics and subtropics [8]. In 2019, the World Health Organization (WHO) estimated that there were around 100 million cases of dengue worldwide, with approximately 390 million people at risk of infection [9].

Dengue Virus

Dengue virus is a single-stranded RNA virus belonging to the Flaviviridae family. It is classified into four distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), which are closely related but antigenically distinct [10]. The virus is transmitted to humans by the bite of infected Aedes mosquitoes, primarily *Aedes aegypti* and *Aedes albopictus*. These mosquitoes are found in tropical and subtropical regions worldwide, and their populations have increased due to factors such as urbanization, increased travel and trade, and climate change [11]. Once a person is infected with the dengue virus, the virus replicates in target cells, such as dendritic cells, monocytes, and macrophages. The virus then spreads throughout the body via the bloodstream, causing a range of symptoms, from mild fever and headache to severe dengue hemorrhagic fever and dengue shock syndrome. Dengue virus has a complex life cycle involving both mosquito and human hosts. Mosquitoes become infected when they feed on the blood of an infected person during the viremic phase of the illness. The virus replicates in the mosquito's gut, and after an incubation period of 8-12 days, the mosquito can transmit the virus to a new host by biting [12].

Transmission of Dengue Infection

Dengue infection is primarily transmitted to humans through the bite of infected Aedes mosquitoes, primarily *Aedes aegypti* and *Aedes albopictus* [13]. These mosquitoes are found in tropical and subtropical regions worldwide, and they typically bite during the daytime, with peak biting activity occurring in the early morning and late afternoon. The transmission cycle of dengue infection involves both human and mosquito hosts [1]. When an infected mosquito bites a person, the virus is transmitted to the person's bloodstream, and the virus then replicates in target cells, such as dendritic cells, monocytes, and macrophages. The infected person becomes contagious after an incubation period of 4-7 days, during which the virus replicates in the body [14]. The person may experience mild symptoms, such as fever, headache, and joint pain, during this time. The person remains contagious for up to 7 days after the onset of symptoms, although some individuals may remain contagious for up to 2 weeks [13]. If an uninfected mosquito bites an infected person during the viremic phase of the illness, the virus is taken up by the mosquito and infects its gut. After an incubation period of 8-12 days, the virus spreads to the mosquito's salivary glands, and the mosquito can then transmit the virus to a new host by biting. The risk of dengue transmission is highest in areas with high mosquito populations and inadequate mosquito control measures [13]. Factors that contribute to the spread of dengue infection include rapid urbanization, increased international travel and trade, and climate change. Prevention efforts are focused on controlling the mosquito population through measures such as using insecticides, eliminating standing water where mosquitoes breed, and using protective clothing and mosquito repellent. Additionally, efforts are underway to develop a safe and effective dengue vaccine [15].

Risk Factors of Dengue Infection

Several risk factors can increase a person's likelihood of contracting dengue infection. Some of the most significant

risk factors include dengue infection is most prevalent in tropical and subtropical regions of the world, including Southeast Asia, Central and South America, Africa, and the Caribbean [16]. Travelling to these areas increases the risk of contracting the virus. Exposure to Aedes mosquitoes, the primary vectors of the dengue virus, increases the risk of infection. Mosquitoes typically bite during the daytime, with peak biting activity occurring in the early morning and late afternoon [17]. Children and young adults are more likely to contract severe forms of dengue infection than older adults. Infants, young children, and pregnant women are at particular risk of severe illness. Individuals with weakened immune systems, such as those with HIV/AIDS or undergoing chemotherapy, are at increased risk of severe dengue infection. Previous infection with one serotype of the dengue virus does not provide immunity to the other serotypes. In fact, a subsequent infection with a different serotype can increase the risk of severe dengue infection [18]. Rapid urbanization increased international travel and trade, and climate change can all contribute to the spread of dengue virus and increase the risk of infection. In areas with high mosquito populations and inadequate mosquito control measures, the risk of dengue infection is higher. It is important to note that not everyone who is exposed to the dengue virus will develop symptoms of the infection. However, the risk of severe illness and complications is higher in certain populations, such as infants, young children, and individuals with weakened immune systems. Taking steps to prevent mosquito bites and practising good mosquito control measures can help reduce the risk of dengue infection [19].

Pathophysiology of Dengue Infection

Dengue infection is caused by a virus known as dengue virus (DENV), which is transmitted to humans through the bite of infected Aedes mosquitoes. The pathophysiology of dengue infection involves several stages and complex interactions between the virus, host immune system, and other factors. After the mosquito bite, the virus enters the human body and replicates in the dendritic cells, monocytes, and macrophages present in the skin. The virus then enters the bloodstream and disseminates to other parts of the body, including the liver, spleen, lymph nodes, and bone marrow [20]. The virus triggers the release of cytokines and chemokines, which activate the innate immune response. This leads to the recruitment of immune cells, including neutrophils, natural killer cells, and dendritic cells, to the site of infection [21]. The innate immune response helps to control the virus replication and limit the spread of infection. The adaptive immune response is initiated when antigen-presenting cells (APCs) present viral antigens to T-cells in the lymph nodes. This leads to the activation of virus-specific T-cells, which help to clear the virus-infected cells. B-cells also produce virus-specific antibodies, which help to neutralize the virus and prevent the further spread of infection. In some cases, the immune response can become dysregulated, leading to immunopathology. This is characterized by the production of excessive cytokines and chemokines, which leads to inflammation and tissue damage. The most severe form of dengue infection, known as dengue hemorrhagic fever (DHF), is thought to result from an exaggerated immune response. DENV can infect and replicate in endothelial cells, which line the blood vessels [21]. This can lead to endothelial dysfunction, characterized by increased vascular permeability and leakage of fluid into the tissues. In severe cases, this can lead to dengue shock syndrome (DSS), a life-threatening complication of dengue infection. the pathophysiology of dengue infection is complex and involves multiple stages, including viral replication and dissemination, innate and adaptive immune responses, immunopathology, and endothelial dysfunction [20]. Understanding the pathophysiology of dengue infection is critical for the development of effective treatments and vaccines to prevent and control this disease.

Clinical Signs and Symptoms

Dengue infection can present with a wide range of clinical signs and symptoms, ranging from mild flu-like symptoms to severe hemorrhagic fever and shock. The incubation period of the dengue virus is usually 4-7 days, after which symptoms typically begin to appear. The most common clinical signs and symptoms of dengue infection are as follows Singh, et al. [22]. A sudden onset of high fever (39-40°C) is a hallmark symptom of dengue infection. Fever occurs due to the immune response to the virus and the release of cytokines. Many patients with dengue infection experience severe headaches, which can be attributed to the inflammatory response of the immune system and the effects of the virus on the central nervous system [23]. Dengue infection often causes severe muscle and joint pain, which is often described as a “breakbone fever [24].” This is due to the inflammatory response and the cytokines released during the immune response. Some patients with dengue infection develop a rash, which usually appears after the fever has subsided. The rash is often described as a maculopapular rash, which is characterized by flat, red spots on the skin. Many patients with dengue infection experience nausea and vomiting, which can be attributed to the effects of the virus on the gastrointestinal tract and the immune response. Patients with dengue infection often experience fatigue, which can be attributed to the immune response and the effects of the virus on the body [25]. In severe cases of dengue infection, patients can experience bleeding from the nose, gums, or under the skin, which can be life-threatening. This is due to the effects of the virus on the blood vessels and the immune response. In the most severe cases, dengue infection can lead to shock, characterized by low blood pressure and

organ failure. This is due to the effects of the virus on the immune system and the blood vessels. The clinical signs and symptoms of dengue infection are varied and can range from mild flu-like symptoms to severe hemorrhagic fever and shock [26]. These symptoms are primarily due to the immune response to the virus and the effects of the virus on various organs and tissues.

Diagnosis of Dengue Infections

Diagnosis of dengue infection requires a combination of clinical assessment, laboratory tests, and imaging studies. Early diagnosis is critical for the appropriate management of patients with dengue infection, as delayed diagnosis and treatment can lead to severe complications and death. However, there are also some hazards associated with the early diagnosis of dengue infection, which I will discuss below. A thorough clinical assessment is critical in the diagnosis of dengue infection. The presence of symptoms such as high fever, headache, muscle and joint pain, rash, nausea, and vomiting can suggest dengue infection [27]. However, clinical assessment alone is not sufficient for the diagnosis of dengue infection. Laboratory tests are required to confirm the diagnosis of dengue infection. The most commonly used laboratory tests are serological tests, which detect antibodies to the dengue virus. These tests include the enzyme-linked immune sorbent assay (ELISA) and the rapid diagnostic test (RDT) [28]. A positive serological test for dengue infection indicates that the patient has been infected with the virus, but it does not differentiate between the different serotypes of the virus. Another laboratory test used in the diagnosis of dengue infection is the polymerase chain reaction (PCR), which detects the presence of viral RNA in the blood. PCR is a more sensitive test than serology, but it is not widely available and can be expensive [29]. Imaging studies such as ultrasound and computed tomography (CT) scans can be used to detect the presence of fluid accumulation in the body cavities, which is a sign of severe dengue infection [30].

Hazards Associated with Early Diagnosis

There are several hazards associated with the early diagnosis of dengue infection, including Serological tests for dengue infection can produce false-positive results, especially in areas where other flaviviruses are endemic [31]. Serological tests can also produce false-negative results in the early stages of infection when antibody levels are low. The symptoms of dengue infection are similar to those of other viral infections, such as chikungunya and Zika virus, which can lead to overdiagnosis of dengue infection [32,33]. Early diagnosis of dengue infection can lead to unnecessary hospitalization and treatment, which can increase the risk of hospital-acquired infections and adverse drug reactions. Focusing on the diagnosis of dengue infection can lead to a delay in the diagnosis of other infections with similar symptoms, such as bacterial infections. the diagnosis of dengue infection requires a combination of clinical assessment, laboratory tests, and imaging studies [34]. Early diagnosis is critical for the appropriate management of patients with dengue infection, but it is also associated with hazards such as false-positive and false-negative results, overdiagnosis, mismanagement, and delayed diagnosis of other infections [34]. Therefore, a careful and thorough evaluation of the patient's symptoms, medical history, and laboratory results is required to make an accurate diagnosis and provide appropriate treatment.

Dengue Infection Treatment and its Challenges

Dengue fever is a viral infection caused by the dengue virus, which is transmitted to humans through the bites of infected Aedes mosquitoes. The symptoms of dengue fever can range from mild to severe and can include high fever, severe headache, muscle and joint pain, nausea, vomiting, and rash. In severe cases, dengue fever can lead to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), which can be life-threatening [35]. Currently, there is no specific antiviral treatment for dengue fever. Treatment is focused on relieving symptoms, providing supportive care, and preventing complications. The following are some of the treatments used for dengue fever: In severe cases of dengue fever, fluid replacement therapy is necessary to prevent dehydration and electrolyte imbalances. Intravenous (IV) fluids and electrolytes are usually given to patients with DHF or DSS. Pain relievers, such as acetaminophen, can help to reduce fever and relieve pain [36]. Rest is important for patients with dengue fever to help their bodies fight the infection. Patients with dengue fever require close monitoring of their vital signs, including blood pressure, pulse, respiratory rate, and urine output. In severe cases of dengue fever, blood transfusions may be necessary to replace blood lost due to bleeding [37].

The difficulties in developing a targeted treatment for dengue fever include the following: The dengue virus has four different serotypes, and each serotype can cause different symptoms. Developing a treatment that is effective against all four serotypes is challenging. The dengue virus replicates rapidly, making it difficult to develop a drug that can stop the virus from replicating. The immune response to dengue fever is complex and can vary from person to person [37]. Developing a treatment that can modulate the immune response without causing harm is challenging. There are no animal models that can accurately mimic the human immune response to dengue fever, making it difficult to test potential treatments. Despite these challenges, research is ongoing to develop a specific drug for dengue fever. Several drugs

are currently in development, including antiviral drugs, vaccines, and immunomodulatory drugs. However, further research is needed to determine the safety and efficacy of these treatments before they can be used to treat dengue fever [37].

Vaccination of Dengue Infection

Dengue is a viral infection caused by the dengue virus, which is transmitted by mosquitoes. The symptoms of dengue infection can range from mild fever to severe bleeding and shock, and it can be fatal in some cases. There is currently no specific antiviral treatment for dengue, and the only way to prevent the infection is through vaccination and mosquito control measures [38]. Vaccines for dengue have been under development for many years, but a highly effective vaccine has not yet been discovered. This is because the dengue virus has four different serotypes, and developing a vaccine that provides protection against all four serotypes is challenging. In addition, the virus can cause both primary and secondary infections [39]. A vaccine that is effective against one serotype may not provide protection against another serotype or may even increase the risk of severe disease in individuals who have previously been infected with a different serotype. Another challenge in developing a dengue vaccine is the need for a vaccine that is safe and effective for all age groups, including children and adults. Some of the vaccine candidates that have been tested in clinical trials have shown promising results in terms of efficacy but have also been associated with adverse events, such as fever and rash [39].

Despite these challenges, there are ongoing efforts to develop a dengue vaccine. One approach is to use live attenuated viruses, which are weakened forms of the virus that can stimulate an immune response without causing disease. Several live attenuated dengue vaccines have been developed and tested in clinical trials, including the CYD-TDV vaccine, which was approved for use in some countries [40]. However, the CYD-TDV vaccine has shown variable efficacy against different serotypes and has been associated with an increased risk of severe disease in some individuals. Another approach to developing a dengue vaccine is to use subunit or recombinant vaccines, which contain only parts of the virus or the virus genes that are responsible for stimulating an immune response [40]. These vaccines may be safer than live attenuated vaccines, but they may also be less effective. Several subunits and recombinant dengue vaccines are currently in clinical trials, including the TAK-003 vaccine, which has shown promising results in Phase 3 clinical trials [41]. In addition to these vaccine candidates, there are ongoing efforts to develop new technologies for vaccine delivery and adjuvants that can enhance the immune response to dengue vaccines. Some researchers are also exploring the use of combination vaccines that can provide protection against multiple diseases, including dengue.

Conclusion

In conclusion, dengue infection is a significant public health issue in many parts of the world. The disease is caused by a virus transmitted by the Aedes mosquito and can lead to severe complications such as hemorrhagic fever and shock syndrome. Although there is no specific treatment for dengue, early detection and management of symptoms can reduce the risk of complications and mortality. Preventing dengue infection involves a multifaceted approach that includes reducing mosquito breeding sites, controlling mosquito populations, and educating the public on prevention measures. Vector control measures, such as the use of insecticides and larvicides, have been effective in reducing mosquito populations, but their sustainability remains a challenge.

There is an urgent need for the development of a dengue vaccine, which would be a game-changer in the fight against the disease. Several vaccine candidates are currently in clinical trials, and their efficacy and safety are being evaluated. Moreover, developing a highly effective and safe vaccine for dengue infection is challenging due to the complex nature of the virus and the need for protection against all four serotypes. However, ongoing research efforts continue to explore new approaches and technologies for developing a dengue vaccine that can provide broad protection against all serotypes and is safe and effective for all age groups.

References

1. Ferreira-de-Lima VH, Lima-Camara TN (2018) Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. Parasites & vectors 11: 1-8.

2. Kamal M, Kenawy MA, Rady MH, Khaled AS, Samy AM, et al. (2018) Mapping the global potential distributions of two arboviral vectors *Aedes aegypti* and Ae. albopictus under changing climate. PloS one 13(12): e0210122.

3. Faraji A, Haas-Stapleton E, Sorensen B, Scholl M, Goodman G, et al. (2021) Toys or tools? Utilization of unmanned aerial systems in mosquito and vector control programs. Journal of Economic Entomology 114(5): 1896-1909.

4. Gubler DJ (2006) Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 277: 3-16.

5. Schlesinger RW (2012) Dengue viruses.

6. Gubler DJ, Clark GG (1995) Dengue/dengue hemorrhagic

fever: the emergence of a global health problem. Emerging infectious diseases 1(2): 55-57.

7. Pinheiro FP, Corber SJ (1997) Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World health statistics quarterly 50(3-4): 161-169.

8. Gubler DJ (1997) Epidemic dengue and dengue hemorrhagic fever: a global public health problem in the 21st century. Emerging infections 1: 1-14.

9. Zeng Z, Zhan J, Chen L, Chen H, Cheng S, et al. (2021) Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017. EClinical Medicine 32: 100712.

10. Tamura T, Zhang J, Madan V, Biswas A, Schwoerer MP, et al. (2022) Generation and characterization of genetically and antigenically diverse infectious clones of dengue virus serotypes 1-4. Emerg Microbes Infect 11(1): 227-239.

11. Murugesan A, Manoharan M (2020) Dengue virus. In: Ennaji MM, et al. (Eds.), Emerging and Reemerging Viral Pathogens. Elsevier, pp: 281-359.

12. Yousaf MZ, Siddique A, Ashfaq UA, Ali M (2018) Scenario of dengue infection & its control in Pakistan: An up—date and way forward. Asian Pacific Journal of Tropical Medicine 11(1): 15-23.

13. Kamgang B, Vazeille M, Tedjou AN, Wilson-Bahun TA, Yougang AP, et al. (2019) Risk of dengue in Central Africa: Vector competence studies with Aedes aegypti and Aedes albopictus (Diptera: Culicidae) populations and dengue 2 virus. PLoS neglected tropical diseases 13(12): e0007985.

14. Dalpadado R, Amarasinghe D, Gunathilaka N, Ariyarathna N (2022) Bionomic aspects of dengue vectors Aedes aegypti and Aedes albopictus at domestic settings in urban, suburban and rural areas in Gampaha District, Western Province of Sri Lanka. Parasites & vectors 15(1): 1-14.

15. Powell JR (2018) Mosquito-borne human viral diseases: why Aedes aegypti. Am J Trop Med Hyg 98(6): 1563-1565.

16. Gan SJ, Leong YQ, Barhanuddin MFHB, Wong ST, Wong SF, et al. (2021) Dengue fever and insecticide resistance in Aedes mosquitoes in Southeast Asia: a review. Parasites & vectors 14(1): 1-19.

17. Yang X, Quam MB, Zhang T, Sang S (2021) Global burden for dengue and the evolving pattern in the past 30 years. J Travel Med 28(8): taab146.

18. Tian N, Zheng JX, Guo ZY, Li LH, Xia S, et al. (2022) Dengue Incidence Trends and Its Burden in Major Endemic Regions from 1990 to 2019. Trop Med Infect Dis 7(8): 180.

19. Lai S, Johansson MA, Yin W, Wardrop NA, van Panhuis WG, et al. (2018) Seasonal and interannual risks of dengue introduction from South-East Asia into China, 2005-2015. PLoS neglected tropical diseases 12(11): e0006743.

20. Tomlin H, Piccinini AM (2018) A complex interplay between the extracellular matrix and the innate immune response to microbial pathogens. Immunology 155(2): 186-201.

21. Pillai AKB, Chu JJH, Mariappan V, JeanPierre AR (2022) Platelets in the pathogenesis of flavivirus disease. Curr Opin Virol 52: 220-228.

22. Singh N, Singh AP, Singh AP (2021) Dengue virus: A review. Indian Journal of Pharmacy and Pharmacology 8(4): 243-247.

23. Trivedi S, Chakravarty A (2022) Neurological complications of dengue fever. Curr Neurol Neurosci Rep 22(8): 515-529.

24. Calderón-Peláez MA, Velandia-Romero ML, Bastidas-Legarda LY, Beltrán EO, Camacho-Ortega SJ, et al. (2019) Dengue virus infection of blood–brain barrier cells: Consequences of severe disease. Frontiers in Microbiology 10: 1435.

25. Herath HM, Hewavithana JS, De Silva C, Kularathna O, Weerasinghe N, et al. (2018) Cerebral vasculitis and lateral rectus palsy–two rare central nervous system complications of dengue fever: two case reports and review of the literature. J Med Case Rep 12(1): 1-6.

26. Mallhi TH, Khan YH, Adnan AS, Tanveer N, Aftab RA, et al. (2021) Dengue-Induced Neurological Complications. Expanded Dengue Syndrome 71-95.

27. Chong ZL, Sekaran SD, Soe HJ, Peramalah D, Rampal S, et al. (2020) Diagnostic accuracy and utility of three dengue diagnostic tests for the diagnosis of acute dengue infection in Malaysia. BMC infectious diseases 20: 1-11.

28. Chaloemwong J, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, et al. (2018) Useful clinical features and hematological parameters for the diagnosis of dengue infection in patients with acute febrile illness: a retrospective study. BMC hematology

18: 1-10.

29. Yin Z, Ramshani Z, Waggoner JJ, Pinsky BA, Senapati S, et al. (2020) A non-optical multiplexed PCR diagnostic platform for serotype-specific detection of dengue virus. Sensors and Actuators B: Chemical 310: 127854.

30. Vanjare H, Mannam P, Mishra A, Karuppusami R, Carey R, et al. (2018) Brain imaging in cases with positive serology for dengue with neurologic symptoms: a clinicoradiologic correlation. AJNR Am J Neuroradiol 39(4): 699-703.

31. WHO (2022) Laboratory testing for Zika virus and dengue virus infections: interim guidance.

32. Lindsey NP, Staples JE, Powell K, Rabe IB, Fischer M, et al. (2018) Ability to serologically confirm recent Zika virus infection in areas with varying past incidence of dengue virus infection in the United States and US territories in 2016. J Clin Microbiol 56(1): e01115-01117.

33. Sharp TM, Fischer M, Muñoz-Jordán JL, Paz-Bailey G, Staples JE, et al. (2019) Dengue and Zika virus diagnostic testing for patients with a clinically compatible illness and risk for infection with both viruses. MMWR Recomm Rep 68(1): 1-10.

34. Wangrangsimakul T, Althaus T, Mukaka M, Kantipong P, Wuthiekanun V, et al. (2018) Causes of acute undifferentiated fever and the utility of biomarkers in Chiangrai, northern Thailand. PLoS Negl Trop Dis 12(5): e0006477.

35. Deng SQ, Yang X, Wei Y, Chen JT, Wang XJ, et al. (2020) A review on dengue vaccine development. Vaccines 8(1): 63.

36. Leowattana W, Leowattana T (2021) Dengue hemorrhagic fever and the liver. World J Hepatol 13(12): 1968-1976.

37. Roy SK, Bhattacharjee S (2021) Dengue virus: epidemiology, biology, and disease aetiology. Canadian Journal of Microbiology 67(10): 687-702.

38. Wang WH, Urbina AN, Chang MR, Assavalapsakul W, Lu PL, et al. (2020) Dengue hemorrhagic fever–A systemic literature review of current perspectives on pathogenesis, prevention and control. J Microbiol Immunol Infect 53(6): 963-978.

39. Wilder-Smith A (2020a) Dengue vaccine development by the year 2020: challenges and prospects. Curr Opin Virol 43: 71-78.

40. Wilder-Smith A (2020b) Dengue vaccine development: status and future. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63(1): 40-44.

41. WHO (2019) Dengue vaccine: WHO position paper, September 2018-recommendations. Vaccine 37(35): 4848-4849.